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Errata

Contributions of authors
Original text:
Marie Westwood and Penny Whiting planned and performed the systematic review and interpretation of evidence. Manuela Joore, Thea van Asselt and Bram Ramaekers planned and performed the cost-effectiveness analyses and interpreted results. Nigel Armstrong and Kelly Lee contributed to planning and interpretation of cost-effectiveness analyses and acquisition of input data for modelling. Kate Misso devised and performed the literature searches and provided information support to the project. Jos Kleijnen and Johan Severens provided senior advice and support to the systematic review and cost-effectiveness analyses, respectively. All parties were involved in drafting and/or commenting on the report.
Revised text:
Marie Westwood and Penny Whiting planned and performed the systematic review and interpretation of evidence. Manuela Joore, Thea van Asselt and Bram Ramaekers planned and performed the cost-effectiveness analyses and interpreted results. Nigel Armstrong contributed to planning and interpretation of cost-effectiveness analyses and acquisition of input data for modelling. Kate Misso devised and performed the literature searches and provided information support to the project. Jos Kleijnen and Johan Severens provided senior advice and support to the systematic review and cost-effectiveness analyses, respectively. All parties were involved in drafting and/or commenting on the report. 
EGFR mutation test accuracy p 48
Original text: "Four of the five studies, which used direct sequencing methods to identify EGFR mutations reported high estimates of specificity (>80%) for OR and specificities ranged from 60 to 80%."
Revised text: "Four of the five studies, which used direct sequencing methods to identify EGFR mutations reported high estimates of specificity (>80%) for OR and sensitivities ranged from 60 to 80%." Original heading text: "Overall survival for patients tested with the Therascreen® EGFR PCR Kit 50 and with direct sequencing of all exon 19-20 mutations 5 " Revised heading text: "Overall survival for patients tested with the Therascreen® EGFR PCR Kit 50 and with direct sequencing of all exon 19-21 mutations 5 " 
